Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
NCT05797506Phase 2Completed
- Sponsor
- University of Rochester
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Sulforaphane (Avmacol Extra Strength) with Placebo (2 arms). Primary endpoint: Change in Plasma 8-Isoprostane From Baseline at 6 months. Started May 2023; status: completed.
02
Drugs
sulforaphane
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05797506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797506.